T follicular helper cell responses to SARS‐CoV ‐2 vaccination among healthy and immunocompromised adults
Immunology & Cell Biology · 2023
DOI: 10.1111/imcb.12635 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology & Cell Biology, 2023. Verfasst von Mollie Ailie Acheson Boyd und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immunovirology and Pathogenesis Program, The Kirby Institute, UNSW, Sydney, NSW, 2052, Australia. Hauptthemen laut MEDLINE: T-Lymphocytes, Helper-Inducer, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, St. Vincent's Clinic Foundation, University of New South Wales.
Abstract (Originalsprache)
The worldwide rollout of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccinations in the last 2 years has produced a multitude of studies investigating T‐cell responses in the peripheral blood and a limited number in secondary lymphoid tissues. As a key component to an effective immune response, vaccine‐specific T follicular helper (Tfh) cells are localized in the draining lymph node (LN) and assist in the selection of highly specific B‐cell clones for the production of neutralizing antibodies. While these cells have been noted in the blood as circulating Tfh (cTfh) cells, they are not often taken into consideration when examining effective CD4 + T‐cell responses, particularly in immunocompromised groups. Furthermore, site‐specific analyses in locations such as the LN have recently become an attractive area of investigation. This is mainly a result of improved sampling methods via ultrasound‐guided fine‐needle biopsy (FNB)/fine‐needle aspiration (FNA), which are less invasive than LN excision and able to be performed longitudinally. While these studies have been undertaken in healthy individuals, data from immunocompromised groups are lacking. This review will focus on both Tfh and cTfh responses after SARS‐CoV‐2 vaccination in healthy and immunocompromised individuals. This area of investigation could identify key characteristics of a successful LN response required for the prevention of infection and viral clearance. This furthermore may highlight responses that could be fine‐tuned to improve vaccine efficacy within immunocompromised groups that are at a risk of more severe disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunovirology and Pathogenesis Program, The Kirby Institute, UNSW, Sydney, NSW, 2052, Australia.
- St Vincent's Hospital, Sydney, NSW, 2010, Australia.
ORCID-Profile: Mollie Ailie Acheson Boyd
Förderung
- National Health and Medical Research Council
- St. Vincent's Clinic Foundation
- University of New South Wales
Zitieren
APA
Boyd, M. A. A., Carey Hoppe, A., Kelleher, A. D., & Munier, C. M. L. (2023). T follicular helper cell responses to SARS‐CoV ‐2 vaccination among healthy and immunocompromised adults. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12635
Vancouver
Boyd MAA, Carey Hoppe A, Kelleher AD, Munier CML. T follicular helper cell responses to SARS‐CoV ‐2 vaccination among healthy and immunocompromised adults. Immunology & Cell Biology. 2023. doi:10.1111/imcb.12635
BibTeX
@article{Boyd2023,
author = {Boyd, Mollie Ailie Acheson and Carey Hoppe, Alexandra and Kelleher, Anthony D and Munier, C Mee Ling},
title = {T follicular helper cell responses to SARS‐CoV ‐2 vaccination among healthy and immunocompromised adults},
journal = {Immunology & Cell Biology},
year = {2023},
doi = {10.1111/imcb.12635}
}
EUVIMED